CRMD 10.90 CorMedix Inc.
| Range: | 2.57-10.17 | Vol Avg: | 825829 | Last Div: | 0 | Changes: | 0.39 |
| Beta: | 1.61 | Cap: | 0.58B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu May 13 2010 | Empoloyees: | 82 | ||
| CUSIP: | 21900C308 | CIK: | 0001410098 | ISIN: | US21900C3088 | Country: | US |
| CEO: | Mr. Joseph Todisco MBA | Website: | https://www.cormedix.com | ||||
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow